Pomalidomide for Treatment of Relapsed and Refractory Multiple Myeloma
Pomalidomide is a third-generation immunomodulatory drug recommended for patients with multiple myeloma refractory to lenalidomide and bortezomib. The safety profile is optimized for application in patients with intensive and continuous anti-tumor treatment. Pomalidomide was approved by the Food and...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
Practical Medicine Publishing House
2015-10-01
|
| Col·lecció: | Клиническая онкогематология |
| Matèries: | |
| Accés en línia: | https://bloodjournal.ru/index.php/coh/article/view/564 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|